Advertisement

Viral Diagnostics

  • Robin K. AveryEmail author
  • Belinda Yen-Lieberman
Chapter

Abstract

This chapter discusses recent developments in diagnostics for cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV), community respiratory viruses (CRVs), parvovirus, hepatitis viruses, HIV, and other viral agents of importance in solid organ and hematopoietic stem cell transplantation.

Keywords

Transplant Viral infections Cytomegalovirus Epstein-Barr virus BK virus Community respiratory viruses Parvovirus Hepatitis viruses 

References

  1. 1.
    Emmadi R, Boonyaratanakornkit JB, Selvarangan R, Shyamala V, Zimmer BL, Williams L, et al. Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays. J Mol Diagn. 2011;13(6):583–604.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis. 2011;52(Suppl 4):S326–30.PubMedGoogle Scholar
  3. 3.
    Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, et al. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant. 2010;10(4):889–99.PubMedGoogle Scholar
  4. 4.
    Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9(2):258–68.PubMedGoogle Scholar
  5. 5.
    Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779–95.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Razonable RR, Humar A, The AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13:93–106.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Hirsch HH, Randhawa P, the AST Infectious Diseases Community of Practice. BK virus in solid organ transplantation. Am J Transplant. 2013;13:179–88.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262–74.PubMedGoogle Scholar
  9. 9.
    Fischer SA, Lu K, the AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;13:9–21.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13(6):581–5.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant. 2005;5(5):1065–70.PubMedGoogle Scholar
  12. 12.
    Caliendo AM, St George K, Kao SY, Allega J, Tan BH, LaFontaine R, et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol. 2000;38(6):2122–7.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Mazzulli T, Drew LW, Yen-Lieberman B, Jekic-McMullen D, Kohn DJ, Isada C, et al. Multicenter comparison of the Digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol. 1999;37(4):958–63.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Humar A, Gregson D, Caliendo AM, McGeer A, Malkan G, Krajden M, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation. 1999;68(9):1305–11.PubMedGoogle Scholar
  15. 15.
    Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002;186(6):829–33.PubMedGoogle Scholar
  16. 16.
    Emery VC, Cope AV, Bowen EF, Gor D, Griffiths PD. The dynamics of human cytomegalovirus replication in vivo. J Exp Med. 1999;190(2):177–82.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Caliendo AM, Yen-Lieberman B, Baptista J, Andersen J, Crumpacker C, Schuurman R, et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol. 2003;41(8):3509–13.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Caliendo AM, Ingersoll J, Fox-Canale AM, Pargman S, Bythwood T, Hayden MK, et al. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol. 2007;45(6):1723–7.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Hirsch HH, Lautenschlager I, Pinsky BA, Cardenoso L, Aslam S, Cobb B, et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis. 2013;56(3):367–73.PubMedGoogle Scholar
  20. 20.
    Casas S, Munoz L, Moure R, Castellote J, Guerra MR, Gonzalez L, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl. 2011;17(10):1205–11.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–24.PubMedGoogle Scholar
  22. 22.
    Nesher L, Shah DP, Ariza-Heredia EJ, et al. Utility of the enzyme-linked immunospot interferon-gamma release assay to predict the risk of cytomegalovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis. 2016;213:1701–7.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation. 2005;79(1):85–90.Google Scholar
  24. 24.
    Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller GG. Interlaboratory comparison of epstein-barr virus viral load assays. Am J Transplant. 2009;9(2):269–79.PubMedGoogle Scholar
  25. 25.
    Caliendo AM. The long road toward standardization of viral load testing for cytomegalovirus. Editorial commentary. Clin Infect Dis. 2013;56:374–5.PubMedGoogle Scholar
  26. 26.
    Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, pre-emptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1687–99.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Lurain NS, Bhorade SM, Pursell KJ, Avery RK, Yeldandi VV, Isada CM, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis. 2002;186(6):760–8.PubMedGoogle Scholar
  28. 28.
    Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35(7):866–72.PubMedGoogle Scholar
  29. 29.
    Allen U, Preiksaitis J. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S87–96.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Green M, Cacciarelli TV, Mazariegos GV, Sigurdsson L, Qu L, Rowe DT, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66(12):1641–4.PubMedGoogle Scholar
  31. 31.
    McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66(12):1604–11.PubMedGoogle Scholar
  32. 32.
    Almeras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis. 2011;13(2):101–8.PubMedGoogle Scholar
  33. 33.
    Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant. 2008;13(6):569–74.PubMedGoogle Scholar
  34. 34.
    Bergallo M, Astegiano S, Sidoti F, Mantovani S, Segoloni GP, Cavallo R, et al. Real-time RT-PCR assay for the quantitation of polyomavirus BK VP1 mRNA levels in urine. Mol Biotechnol. 2010;45(1):82–6.PubMedGoogle Scholar
  35. 35.
    Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79(10):1277–86.PubMedGoogle Scholar
  36. 36.
    Gilis L, Morisset S, Billaud G, et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49:664–70.PubMedGoogle Scholar
  37. 37.
    Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis. 2006;8(2):95–101.PubMedGoogle Scholar
  38. 38.
    Kumar D, Husain S, Chen MH, Moussa G, Himsworth D, Manuel O, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation. 2010;89(8):1028–33.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521–6.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65(5):1–54.PubMedGoogle Scholar
  41. 41.
    Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–63.PubMedGoogle Scholar
  42. 42.
    Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26(8):862–4.PubMedGoogle Scholar
  43. 43.
    Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Lyon GM. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–3.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Eid AJ, Chen SF. and the AST Infectious Diseases Community of Practice. Human parvovirus B19 in solid organ transplantation. Am J Transplant. 2013;13:201–5.PubMedGoogle Scholar
  45. 45.
    Ki CS, Kim IS, Kim JW, Lee NY, Kim SH, Lee KW, et al. Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant. 2005;19(6):751–5.PubMedGoogle Scholar
  46. 46.
    Barzon L, Murer L, Pacenti M, Biasolo MA, Vella MD, Ghirardo G, et al. Detection of viral DNA in kidney graft preservation and washing solutions is predictive of posttransplant infections in pediatric recipients. J Infect Dis. 2009;200(9):1425–33.PubMedGoogle Scholar
  47. 47.
    Moal V, Legris T, Burtey S, Morange S, Purgus R, Dussol B, et al. Infection with hepatitis E virus in kidney transplant recipients in southeastern France. J Med Virol. 2013;85:462–71.PubMedGoogle Scholar
  48. 48.
    Levitsky J, Doucette K. Viral hepatitis in solid organ transplantation. Am J Transplant. 2013;13:147–68.PubMedGoogle Scholar
  49. 49.
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation. 1995;59(2):230–4.PubMedGoogle Scholar
  50. 50.
    Pinney SP, Cheema FH, Hammond K, Chen JM, Edwards NM, Mancini D. Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J Heart Lung Transplant. 2005;24(1):34–7.PubMedGoogle Scholar
  51. 51.
    Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant. 2001;1(2):185–91.PubMedGoogle Scholar
  52. 52.
    Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006;296(15):1843–50.PubMedGoogle Scholar
  53. 53.
    Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant. 2004;4(12):2032–7.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. Am J Kidney Dis. 2012;60(1):112–20.PubMedGoogle Scholar
  55. 55.
    Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53(5):1374–81.PubMedGoogle Scholar
  56. 56.
    Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355–65.PubMedGoogle Scholar
  58. 58.
    Muller E, Barday Z, Mendelson M, Kahn D. Renal transplantation between HIV-positive donors and recipients justified. S Afr Med J. 2012;102(6):497–8.PubMedPubMedCentralGoogle Scholar
  59. 59.
  60. 60.
  61. 61.
    Blumberg EA, Rogers CC, the AST Infectious Diseases Community of Practice. Human immunodeficiency virus in solid organ transplantation. Am J Transplant. 2013;13:169–78.PubMedGoogle Scholar
  62. 62.
    Ison MG, Llata E, Conover CS, Friedewald JJ, Gerber SI, Grigoryan A, et al. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant. 2011;11(6):1218–25.PubMedPubMedCentralGoogle Scholar
  63. 63.
    HIV transmitted from a living organ donor--New York City, 2009. MMWR Morb Mortal Wkly Rep. 2011;60(10):297–301.Google Scholar
  64. 64.
    Ison MG, Stosor V. Transplantation of high-risk donor organs: a survey of US solid organ transplant center practices as reported by transplant infectious diseases physicians. Clin Transplant. 2009;23(6):866–73.PubMedGoogle Scholar
  65. 65.
    Seem DL, Lee I, Umscheid CA, Kuehnert MJ, United States Public Health Service. PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Transmission Through Organ Transplantation. Public Health Rep. 2013;128:247–343.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Mahony JB, Blackhouse G, Babwah J, Smieja M, Buracond S, Chong S, et al. Cost analysis of multiplex PCR testing for diagnosing respiratory virus infections. J Clin Microbiol. 2009;47(9):2812–7.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Infectious DiseaseJohns HopkinsBaltimoreUSA
  2. 2.Pathology and Laboratory Medicine Institute, Cleveland Clinic, Department of Laboratory MedicineClevelandUSA

Personalised recommendations